Results 121 to 130 of about 101,157 (242)

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety against both drug‐susceptible and drug‐resistant Mycobacterium tuberculosis (Mtb) strains.
Md. Mahmudul Islam, Md. Zahid Hasan, Md. Touki Tahamid Tusar, Md. Yeamin Hossain, Md. Motaher Hossain, Md. Abdulla Al Jubayed, Md. Jubaer‐Al‐Abedin, Sheikh Soikot, Shanzida Akther, Jahid Bhuyian, Hafizur Rahman Gazi, B. M. Mahmudul Hasan, Md. Shofiul Azam, Md. Enamul Haque, Abdullah‐Al‐Jubayer, Md. Faruk Hasan, F. M. Ali Haydar, Md. Khalekuzzaman, Md. Torequl Islam, Sohel Hasan   +19 more
wiley   +1 more source

Hansen's disease in association with immune reconstitution inflammatory syndrome

Indian Dermatology Online Journal, 2016
Immune reconstitution inflammatory syndrome is characterized by a paradoxical worsening of an existing infection or disease process, soon after initiation of highly active antiretroviral therapy.
Anju George, Suja Vidyadharan
doaj   +1 more source

Non-clinical outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review [PDF]

, 2010
The impacts of antiretroviral therapy on quality of life, mental health, labor productivity, and economic wellbeing for people living with HIV/AIDS in developing countries are only beginning to be measured.
Beard, Jennifer, Feeley, Frank, Rosen, Sydney   +2 more
core   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

Oral candidiasis as a clinical marker of highly active antiretroviral treatment failure in HIV-infected patients

Infectio
Introduction: Oral candidiasis is an opportunistic infection that is readily detectable in the clinic. It has been used to assess the immune status of HIV patients as well as the effectiveness of highly active antiretroviral therapy.
Sandra Lopez-Verdin, Amalia Torrecilla-Ramirez, Ana Cristina Horta-Sandoval, Jaime Federico Andrade-Villanueva, Ronell Bologna-Molina   +4 more
doaj   +1 more source

Etiologic Characteristics of Enterocolitis in Hospitalized HIV-Infected Patients for 3-Year Period (2013-2015)

Acta Medica Bulgarica, 2016
Diarrhea is the most common gastrointestinal symptom in HIV-infected patients. The incidence and severity of diarrhea increase with progression of the immune defi ciency.
Yancheva N., Strashimirov D., Elenkov I., Tchervenyakova T., Tomova P., Tcvetkova N., Yankova M., Tomov T., Nikolova M.   +8 more
doaj   +1 more source

Scaling Up HIV Self‐Testing in Africa: Insights From National Programmatic Data in Eight Countries

Journal of the International AIDS Society, Volume 29, Issue 5, May 2026.
ABSTRACT Introduction Evidence from routine, national programme data on HIV self‐testing (HIVST) scale‐up is limited. This study examines HIVST scale‐up in eight African countries, describing how HIVST has been integrated into testing strategies and how testing coverage, test positivity, and linkage to antiretroviral therapy (ART) have evolved ...
Adrien Allorant, Anne Bekelynck, Aliza Monroe‐Wise, Carlota Baptista da Silva, Thato Chidarikire, Olanrewaju Edun, Leonid Joaquim, Christine Kisia, Joseph Larmarange, Johnson John Lyimo, Juma McOllogi James, Christine Musanhu, Getrude Ncube, Isabel Sathane, Arlette Simo‐Fotso, Geoffrey Taasi, Cheryl Case Johnson   +16 more
wiley   +1 more source

2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C

Journal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
ABSTRACT In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal ...
Tarekegn Hiwot, Forbes D. Porter, Tatiana Bremova‐Ertl, Uma Ramaswami, Caroline Hastings, Bénédicte Héron, Justin Hopkin, Joella Melville, Hernan Amartino, Mireia del Toro, Federica Deodato, Fatih Ezgü, Paul Gissen, James B. Gibson, Can Ficicioglu, Roberto Giugliani, Orna Staretz‐Chacham, Frances Platt, Nathalie Guffon, Kristina Julich, Nikola Kresojević, Anna Lehman, Yann Nadjar, Susanne A. Schneider, Simon Jones, Eugen Mengel, Michel Tchan, Mark Walterfang, Ozlem Goker‐Alpan, Charlotte Dawson, Sandra Cowie, Toni Mathieson, Elizabeth Berry‐Kravis, Marc C. Patterson   +33 more
wiley   +1 more source

Discovery of 4‐Quinazolinone‐Containing Phenylalanine Derivatives as Potent, Resistant‐Tolerant HIV Capsid Inhibitors

MedComm, Volume 7, Issue 5, May 2026.
Novel phenylalanine derivatives were identified as HIV‐1 capsid inhibitors. IC‐2i showed significant anti‐HIV‐1 activity at picomolar concentrations. ABSTRACT The HIV‐1 capsid (CA) is a validated antiviral target that plays critical roles in both the early and late stages of the viral life cycle.
Xujie Zhang, Lin Sun, Laura Walsham, Yuexi Ma, Dang Ding, Mei Wang, Fabao Zhao, Jian Zhang, Zhao Wang, Shujing Xu, Xiangyi Jiang, Yang Zhou, Erik De Clercq, Christophe Pannecouque, Chin‐Ho Chen, David C. Goldstone, Xinyong Liu, Alexej Dick, Peng Zhan   +18 more
wiley   +1 more source

Pharmacokinetics, Pharmacodynamics, Efficacy and Drug Resistance Selection of Injectable Long‐Acting Lenacapavir Pre‐Exposure Prophylaxis (PrEP) Against HIV

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Oral pre‐exposure prophylaxis (PrEP) can substantially reduce HIV infection risk when taken as prescribed. However, many individuals struggle adhering to the daily regimen. Twice‐yearly injections of the novel HIV capsid inhibitor lenacapavir (LEN) demonstrated potential in recent PrEP trials.
Hee‐yeong Kim, Antonia Liebenberg, Lanxin Zhang, Max von Kleist   +3 more
wiley   +1 more source